Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,600
Closed -$763K 11266
2025
Q4
$763K Hold
5,600
﹤0.01% 5800
2025
Q3
$826K Buy
+5,600
New +$777K ﹤0.01% 5722
2025
Q2
Sell
-4,400
Closed -$526K 10910
2025
Q1
$526K Buy
+4,400
New +$545K ﹤0.01% 5818
2024
Q3
Sell
-11,200
Closed -$1.52M 10138
2024
Q2
$1.52M Buy
+11,200
New +$1.52M ﹤0.01% 4032
2018
Q1
Sell
-35,700
Closed -$2.44M 8217
2017
Q4
$2.44M Buy
+35,700
New +$2.37M ﹤0.01% 3022
2015
Q1
Sell
-100
Closed -$4K 9466
2014
Q4
$4K Buy
+100
New +$3.66K ﹤0.01% 9136

Other funds holding XYL

UBS Group's XYL Position: Q1 2026 in Review

UBS Group reduced its Xylem (XYL) stake by 10% in Q1 2026, selling an estimated $16.1M and leaving 1,075,083 shares worth $128M. The position accounts for 0.02% of the portfolio, ranked #862.

UBS Group first reported a position in XYL in Q4 2014 and has held it in 46 quarters since. The position peaked at $235M in Q4 2024. 1,107 funds tracked by Wall St. Rank hold XYL as of Q1 2026.

  • UBS Group held 1,075,083 shares of Xylem worth $128M as of Q1 2026.
  • UBS Group sold 122,952 Xylem shares in Q1 2026, an estimated $16.1M.
  • Xylem made up 0.02% of UBS Group's portfolio in Q1 2026, its #862 holding.
  • UBS Group first reported a position in Xylem in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Xylem position peaked at $235M in Q4 2024.
  • 1,107 funds tracked by Wall St. Rank held Xylem as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.